Clearmind Medicine Inc. (CMND) is a Vancouver-based, clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens, led by its lead candidate CMND-100 for alcohol use disorder. On Wednesday, Nov. 18, the stock traded at $3.03, down 16.53% from the previous session's close of $3.63, confirming a decisive move lower during the regular session. No verified company-specific catalyst was identified for the day's decline. The selling instead extends a weeks-long erosion in which investors have repeatedly discounted procedural clinical updates and repositioned for potential future financing needs.
No verified news or fundamental catalyst found for the Nov. 18 move after reviewing company disclosures, wire services and exchange filings. The most recent corporate announcement came two days earlier, on Nov. 16, when Clearmind said it had completed patient enrollment for Part C of its Phase I/IIa trial of CMND-100. That release contained no efficacy or pharmacokinetic results, and the shares declined in the sessions that followed it. With no fresh disclosure on Wednesday, the price action is most consistent with thin, order-driven trading in a micro-cap where a small number of market orders can move the quote materially. The stock's average absolute daily move over the past 60 sessions is about 4.4%, and today's decline is roughly 3.8 times that figure — a large move, but not unprecedented: only one session in that window, a 31.8% drop on Sept. 4, exceeded it.
The Nov. 16 announcement marked full enrollment in Part C of the CMND-100 program, a randomized, double-blind, placebo-controlled multiple-dose study assessing safety, tolerability and pharmacokinetics at sites including Johns Hopkins, Yale, Tel Aviv Sourasky and Hadassah. Part C follows the first Part B cohort in moderate-to-severe alcohol use disorder patients and earlier healthy-volunteer safety work. Enrollment completion, however, is an operational milestone rather than a data event. With results still pending, investors have been asked to fund additional waiting time without new evidence of efficacy — a dynamic that typically weighs on early-stage biotech valuations, and one that the market appears to have treated as a reason to reduce exposure rather than add it.
The share structure bears the arithmetic signature of repeated reverse splits: a 52-week range spanning roughly $1,274 on the high side to just above $3, alongside reported book value of about $48 per share, is consistent with serial share consolidations rather than organic price discovery. Clearmind's Nov. 16 filing also incorporated the press release by reference into its existing Form F-3 registration statements, a standard shelf mechanism that keeps the prospect of additional equity issuance in view. For a company with a sub-$2 million market capitalization and no revenue, that structural overhang is a persistent valuation constraint and a plausible secondary contributor to selling pressure.
Volume has not confirmed the decline with institutional force. Ten-day average volume is around 6,200 shares, far below the roughly 57,000-share three-month average, and Wednesday's tape featured small, sporadic prints. That combination — a double-digit percentage decline on light turnover — points to liquidity-driven price discovery rather than broad distribution. The move appears idiosyncratic: no matching sector-wide catalyst was identified among psychedelic-development peers, and the decline is divorced from the direction of the major equity indices. Technically, the shares are trading well below their 50-day and 200-day moving averages, having broken through the $4.00 and $3.63 levels during the prior two sessions and now testing the $3.00 round number, with the 52-week low just above $3.24 already breached.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 30 out of 100. Verified news was weak: the only recent disclosure was a routine enrollment-completion update, material in a procedural sense but carrying no clinical readout relative to the company's size. The price move was moderately unusual — about 3.8 times the stock's typical daily swing, with only one larger session in the past 60 — but it occurred on below-average volume and follows a familiar pattern of large percentage swings. Weak news and a mid-range anomaly combine into a low-to-moderate score.
Attention now centers on the release of Part C safety, tolerability and pharmacokinetic data, followed by the Part B efficacy readout in patients with moderate-to-severe alcohol use disorder — the events that will define the program's value. Investors will also watch the company's cash position and burn rate against its roughly $15.9 million in reported cash, and any update on Nasdaq minimum bid price compliance given the collapse in the share price. Additional capital raises, warrant exercises or further consolidations remain live risks. On the upside, favorable data or a regulatory milestone could change the narrative quickly, though liquidity constraints mean both directions are likely to remain volatile.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. Bots vary widely by strategy, timeframe, performance metrics and traded symbols, allowing users to compare approaches side by side. For readers tracking volatile names like this one, the page offers a useful starting point for research. Explore the current leaderboard to see which strategies are working in today's market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CMND saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 103 similar instances where the indicator turned negative. In 97 of the 103 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CMND turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 36 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CMND entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
CMND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.443) is normal, around the industry mean (3.596). P/E Ratio (-0.096) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CMND’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMND’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology